FMA Wealth Management LLC Makes New $271,000 Investment in Eli Lilly and Company (NYSE:LLY)

FMA Wealth Management LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 465 shares of the company’s stock, valued at approximately $271,000.

A number of other hedge funds have also modified their holdings of LLY. Avantax Planning Partners Inc. grew its stake in Eli Lilly and Company by 48.1% in the 3rd quarter. Avantax Planning Partners Inc. now owns 3,883 shares of the company’s stock valued at $2,086,000 after acquiring an additional 1,261 shares during the last quarter. Lincoln National Corp increased its position in Eli Lilly and Company by 10.0% during the 3rd quarter. Lincoln National Corp now owns 14,797 shares of the company’s stock worth $7,948,000 after purchasing an additional 1,351 shares in the last quarter. Black Swift Group LLC raised its stake in Eli Lilly and Company by 199.1% in the 3rd quarter. Black Swift Group LLC now owns 8,000 shares of the company’s stock valued at $4,297,000 after purchasing an additional 5,325 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in Eli Lilly and Company by 49.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 622,010 shares of the company’s stock valued at $334,100,000 after purchasing an additional 205,704 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Eli Lilly and Company by 4.0% during the third quarter. Assenagon Asset Management S.A. now owns 474,940 shares of the company’s stock valued at $255,105,000 after buying an additional 18,079 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $1.02 on Friday, hitting $807.43. The company’s stock had a trading volume of 1,758,200 shares, compared to its average volume of 2,993,883. Eli Lilly and Company has a one year low of $419.80 and a one year high of $820.60. The firm has a market cap of $767.39 billion, a P/E ratio of 119.20, a price-to-earnings-growth ratio of 1.75 and a beta of 0.37. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company has a fifty day moving average price of $764.43 and a 200-day moving average price of $690.85.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.62 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 13.78 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be given a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analyst Ratings Changes

A number of analysts have issued reports on LLY shares. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Barclays upped their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $769.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.